Literature DB >> 1778705

Costs of breast cancer and the cost-effectiveness of breast cancer screening.

A Elixhauser1.   

Abstract

Breast cancer is the second leading cause of death by cancer among women in the United States. The total cost of illness for breast cancer has been estimated to be $3.8 billion, of which $1.8 billion represents medical care costs. It has been estimated that breast cancer detected early is considerably less expensive than when the tumor is discovered at a later stage. Mass screening using mammography can improve early detection by as much as 15-35%. Cost-effectiveness studies have estimated that the costs of breast cancer screening range between $13,200 and $28,000 per year of life saved. The cost-effectiveness of breast cancer screening in the 40-49-year-old age group is controversial. Mass screening for breast cancer will probably increase total health care costs, but when all economic costs are included, screening appears to be more cost-effective than not screening.

Entities:  

Mesh:

Year:  1991        PMID: 1778705     DOI: 10.1017/s0266462300007169

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  9 in total

1.  A comparison of breast and cervical cancer legislation and screening in Georgia, North Carolina, and South Carolina.

Authors:  Stephanie Miles-Richardson; Daniel Blumenthal; Ernest Alema-Mensah
Journal:  J Health Care Poor Underserved       Date:  2012-05

2.  Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

Authors:  L Bolondi; S Sofia; S Siringo; S Gaiani; A Casali; G Zironi; F Piscaglia; L Gramantieri; M Zanetti; M Sherman
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

Review 3.  Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.

Authors:  H M Bryson; G L Plosker
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

4.  Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK.

Authors:  M Nuijten; L Meester; F Waibel; S Wait
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

5.  Patient Navigation Can Improve Breast Cancer Outcomes among African American Women in Chicago: Insights from a Modeling Study.

Authors:  Aditya S Khanna; Bryan Brickman; Michael Cronin; Nyahne Q Bergeron; John R Scheel; Joseph Hibdon; Elizabeth A Calhoun; Karriem S Watson; Shaila M Strayhorn; Yamilé Molina
Journal:  J Urban Health       Date:  2022-08-08       Impact factor: 5.801

6.  Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines.

Authors:  Charlotte Hsieh Ahern; Yu Shen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-03       Impact factor: 4.254

7.  Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial.

Authors:  E Lidbrink; J Elfving; J Frisell; E Jonsson
Journal:  BMJ       Date:  1996-02-03

8.  Estrogenic and DNA-damaging activity of Red No. 3 in human breast cancer cells.

Authors:  C Dees; M Askari; S Garrett; K Gehrs; D Henley; C M Ardies
Journal:  Environ Health Perspect       Date:  1997-04       Impact factor: 9.031

9.  Cost effectiveness of breast cancer screening using mammography; a systematic review.

Authors:  Arash Rashidian; Eshagh Barfar; Hamed Hosseini; Shirin Nosratnejad; Esmat Barooti
Journal:  Iran J Public Health       Date:  2013-04-01       Impact factor: 1.429

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.